Hims & Hers Health (NYSE:HIMS – Get Free Report)‘s stock had its “sell” rating restated by analysts at Citigroup in a research note issued on Thursday,Benzinga reports. They currently have a $27.00 price objective on the stock. Citigroup’s price target would suggest a potential downside of 25.03% from the company’s previous close.
Several other equities analysts also recently commented on HIMS. Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. BTIG Research assumed coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Piper Sandler boosted their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, February 25th. TD Cowen restated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Finally, Bank of America boosted their target price on Hims & Hers Health from $18.00 to $21.00 and gave the stock an “underperform” rating in a research report on Thursday, February 20th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $37.23.
View Our Latest Analysis on Hims & Hers Health
Hims & Hers Health Stock Performance
NYSE:HIMS opened at $36.01 on Thursday. The stock has a 50-day simple moving average of $37.45 and a two-hundred day simple moving average of $27.31. Hims & Hers Health has a 52-week low of $11.20 and a 52-week high of $72.98. The firm has a market capitalization of $8.00 billion, a PE ratio of 81.85 and a beta of 1.37.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Equities analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, CEO Andrew Dudum sold 78,127 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $29.62, for a total transaction of $2,314,121.74. Following the transaction, the chief executive officer now owns 109,956 shares of the company’s stock, valued at approximately $3,256,896.72. This represents a 41.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Soleil Boughton sold 4,152 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now directly owns 157,345 shares in the company, valued at approximately $9,549,268.05. This represents a 2.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,062,011 shares of company stock valued at $36,892,724 over the last ninety days. 17.71% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the business. IronOak Wealth LLC. bought a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $922,000. Kilter Group LLC bought a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $1,053,000. Cim LLC grew its stake in shares of Hims & Hers Health by 1.0% during the fourth quarter. Cim LLC now owns 71,869 shares of the company’s stock valued at $1,738,000 after buying an additional 694 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $4,900,000. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $200,000. Institutional investors own 63.52% of the company’s stock.
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Recommended Stories
Receive News & Ratings for Hims & Hers Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hims & Hers Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
